Company Overview

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

  • Name

    Novo Nordisk A/S

  • CEO

    Mr. Lars Fruergaard Jorgensen

  • Website

    www.novonordisk.com

  • Sector

    Pharmaceuticals

  • Year Founded

    1923

Profile

  • Market Cap

    DKK 4,071.85B

  • EV

    DKK 4,066.25B

  • Shares Out

    4,433.15M

  • Revenue

    DKK 258B

  • Employees

    69,260

Margins

  • Gross

    84.53%

  • EBITDA

    49.05%

  • Operating

    45.96%

  • Pre-Tax

    43.77%

  • Net

    34.84%

  • FCF

    31.46%

Returns (5Yr Avg)

  • ROA

    29.76%

  • ROTA

    140.26%

  • ROE

    78.16%

  • ROCE

    78.38%

  • ROIC

    32.2%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    DKK 967.54

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    DKK 62.65B

  • Net Debt

    -DKK 5,594M

  • Debt/Equity

    0.51

  • EBIT/Interest

    218.77

Growth (CAGR)

  • Rev 3Yr

    25.7%

  • Rev 5Yr

    17.17%

  • Rev 10Yr

    11.85%

  • Dil EPS 3Yr

    28.06%

  • Dil EPS 5Yr

    20.75%

  • Dil EPS 10Yr

    15.21%

  • Rev Fwd 2Yr

    22.58%

  • EBITDA Fwd 2Yr

    25.51%

  • EPS Fwd 2Yr

    24.61%

  • EPS LT Growth Est

    21.81%

Dividends

  • Yield

  • Payout

    49.15%

  • DPS

    DKK 9.9

  • DPS Growth 3Yr

    28.42%

  • DPS Growth 5Yr

    19.43%

  • DPS Growth 10Yr

    15.97%

  • DPS Growth Fwd 2Yr

    26.45%

CPSE:NOVO B